A pilot study investigating intralesional injections
of hyaluronic acid for treatment of Peyronie’s
disease has shown encouraging preliminary results.
Peyronie's disease (PD) is an acquired, localized
fibrotic disorder characterized by the deposition of
collagen and fibrin in the form of plaque on the
tunica albuginea of the penis, just under the skin.
These plaques cause the penis to lose some of its
flexibility.
The penis starts to curve, making intercourse
difficult or impossible.
Its pathophysiology is unknown and frequently
results in penile deformity, penile pain, and
erectile dysfunction leading to a significant
negative impact on patient quality of life, with
associated rates of significant depression up to
48%. Recent prevalence estimates vary from 3.2% to
8.9%.
Scientists are not certain what causes Peyronie’s
disease, but many believe it stems from a wound that
is not healing properly.
This prospective, multicenter, pilot study assessing
the efficacy of hyaluronic acid as intralesional
treatment for patients with PD showed encouraging
preliminary results for improvement of plaque size,
penile curvature, and overall sexual satisfaction.
This therapeutic approach seems to be preferably
indicated in the early (active) phase of the
disease. Intralesional treatment with hyaluronic
acid is easy to perform and well tolerated, with
null risk of local or systemic side effects.
For more information
SEXUAL MEDICINE
Intralesional Injection of Hyaluronic Acid in
Patients Affected With Peyronie's Disease:
Preliminary Results From a Prospective, Multicenter,
Pilot Study
Alessandro Zucchi, MD, Elisabetta Costantini, MD,
Tommaso Cai, MD, Giorgio Cavallini, MD, Giovanni Liguori, MD, Vincenzo Favilla, MD, Gaetano De
Grande, MD, Giuseppe D'Achille, MD, Mauro Silvani,
MD, Giorgio Franco, MD, Alessandro Palmieri, MD,
Paolo Verze, MD, PhD, Vincenzo Mirone, MD.
Link...
MDN |